Scientists have successfully increased the lifespan of animals and there are first studies which describe how we might reverse aging. So how could we one day rever aging?
đŹ Subscribe for more awesome biomedical research: https://bit.ly/2SRMqhC
Continue reading “Scientists Uncover How to Reverse Aging” »
Alector, a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, has announced the initiation of the first-in-human Phase 1 trial of AL044. The study is investigating the safety profile, pharmacokinetics (PK), pharmacodynamics (PD) and target engagement of AL044 in healthy adults.
Longevity. Technology: Headquartered in South San Francisco, California, Alector is aiming to develop an unmatched pipeline of novel potential medicines based on insights into immunology, neurology and human genetics. The companyâs therapeutic candidates are intended to harness the bodyâs innate power to heal itself, and Alector is pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases, and innate immuno-oncology.
Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered, and is developing, a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brainâs immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alectorâs immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimerâs disease.
What is limb regeneration and what species possess it? How is it achieved? What does this tell us about intelligence in biological systems and how could this information be exploited to develop human therapeutics? Well, in this video, we discuss many of these topics with Dr Michael Levin, Principal Investigator at Tufts University, whose lab studies anatomical and behavioural decision-making at multiple scales of biological, artificial, and hybrid systems.
Find Michael on Twitter â https://twitter.com/drmichaellevin.
Continue reading “Regeneration, Intelligence in Life & Memory â Dr Michael Levin” »
A small California biotech emerged from stealth last year to go after drug discoveryâs âdata problem,â and now the AI outfit has announced its first public partnership. Terray Therapeutics put out word Wednesday that it reached a deal with Calico Life Sciences, the Google-backed anti-aging biotech co-founded by industry legend.
Celine halioua drops into a crouch and greets Bocce, a Chihuahua-dachshund mix with soulful brown eyes, like a long-lost friend. âOh my God, youâre so beautiful!â she chirps. The two have just met in an upstairs room at Muttville Senior Dog Rescue in San Francisco, where light streams in through the open windows and urine occasionally streams onto the floor. About a dozen elderly dogs, none taller than a kneecap, putter around on the gray linoleum or nap on blankets. When Halioua kneels, her dark hair tumbling over her shoulder, Bocce rests his head blissfully in her lap.
A tragedy of human-canine relations is that a 10-year-old dog such as Bocce is old, while a 28-year-old person such as Halioua is in the prime of life. Bocce is one of the lucky ones. Many dogs can only dream of living as long as he likely will, because dog lifespan is inversely correlated with body size. Itâs the opposite of the wider pattern in the animal kingdom, where elephants easily outlast mice, which in turn outlive mosquitoes. A Chihuahua can expect roughly 15 years of life; an Irish wolfhound or Great Dane around seven or eight.
Halioua hopes that the startup whose name is emblazoned on her slim black T-shirtâ Loyal âcan start to fix this bug in humanityâs 14,000-year-plus wolf bioengineering project. The company, which she founded in 2019 and leads as CEO, is developing drugs to delay aging in dogs and extend their healthy lifespan. She has raised around $58 million and has two drugs in development. In a few years, she hopes to have the first commercial drugâfor any speciesâto state on the label that it delays aging or extends lifespan. That alone would be a triumph, but Halioua sees it as a springboard to a still greater feat: creating similar drugs for humans.
Genflow has announced that its adeno-associated virus (AAV) research and development programme in Estonia has received a non-dilutive grant award of âŹ250,000 from the Applied Research Programme of Enterprise Estonia, an Estonian governmental institution designed to stimulate business growth in the country.
Longevity. Technology: Genflowâs research programme is focused on the development of an antiaging gene therapy platform designed to target nearly 100 million patients worldwide who suffer from Wernerâs syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis, an advanced form of NAFLD, as well as other major clinical disorders.
This R&D is a collaborative project between Genflow and IVEX lab OĂ, an Estonian company specialising in the research and development of biotech therapeutics.
Far-thinking billionaires are funding innovative research aimed at discovering methods to slow and reverse pathological aging processes. The objective is to accelerate scientific advances that will enable humans to enjoy longer and healthier life spans.
Scientifically reviewed by Dr. Gary Gonzalez, MD, in May 2022. Written by: Michael Downey, Health & Wellness Author.
Prior to this, it was assumed that egg cells (oocytes) would contain a complex array of factors needed to reprogram a somatic cell into becoming an embryonic cell. After all, the feat of transforming an aged egg cell and reprogramming it to make a new animal must be controlled by many factors present in the egg cell, or so they thought. Takahashi and Yamanaka turned this idea upside down when they showed that just four of the Yamanaka factors were needed to achieve this transformation.
They used the Yamanaka factors to reprogram adult mouse fibroblasts (connective tissue cells) back to an embryonic state called pluripotency, a state where the cell behaves like an embryonic stem cell and can become any other cell type in the body.
Continue reading “Yamanaka Factors and Partial Cellular Reprogramming” »
Mounting evidence suggests that humans may have the biological hardware to benefit from some aspects of hibernation. Switching on these mechanisms could treat cardiac arrest, boost longevity and help people travel further into space.
âTranshumanismâ â The intellectual and cultural movement that affirms the possibility and desirability of fundamentally improving the human condition through applied reason, especially by developing and making widely available technologies to eliminate aging and to greatly enhance human intellectual, physical, and psychological capacities. â whatistranshumanism.org.
ââŠI suppose Iâve been looking for Eden all my life. I think we all have. And I think that primeval communion between humanity and the rest of life did exist once, and perhaps still does in some pockets. But it is not available to modern people except in memory or longing. And the search can be damaging if it distracts you from the fact that, whatever horrors humanity unleashes, the world is still a wonder if we can just get out of our anxious minds long enough to see it. Which is easier written than done.
Both sides in the argument that runs through Alexandria my latest novel ânature versus culture, body versus mind, human versus machineâfind that their worldview has holes in. Thatâs part of the point, I think. Our world is being eaten by this great, terrible machine, but the machine is a manifestation of us.
If my worldview has changed it is only to reveal to me that any âenemyâ we might have is lodged firmly in each of our hearts, and that there is nowhere to escape to that doesnât lead through it.â
Continue reading “**YOUTUBE Talk with Author PAUL KINGSNORTH about ‘The Coming Transhuman Future’” »
